Siemens booked record quarterly orders of €34.8bn on Thursday, up 58%, and record free cash flow of €12.1bn for its fiscal year to September. It raised its dividend to €5.50, lifted its mid-term growth targets and set out plans to hand part of its Siemens Healthineers stake directly to shareholders. Earnings per share for the year beat the company's own raised guidance.
The figures arrive before the Xetra open on a stock that has lagged this autumn. Siemens closed last week at €263.65, about 9% below its end-August level, having dropped 5.12% in the week to 23 October to a weekly close of €256.80.
Fiscal 2026 in numbers
- €34.8bn fourth-quarter orders, up 58%
- €12.1bn free cash flow for the year, a record
- €5.50 proposed dividend, up from €5.35
A Record Fourth Quarter
In the three months to 30 September revenue rose 11% to €23.7bn, or 10% on a comparable basis, and the book-to-bill ratio, orders against revenue, reached 1.47. Profit in the Industrial Business rose 22% to a record €3.9bn, a margin of 16.8%. Net income rose 32% to €2.4bn and earnings per share before purchase price allocation (EPS pre-PPA) were €3.01. Free cash flow for the quarter was a record €5.6bn.
Mobility and Smart Infrastructure led the growth in orders, the company said, and Smart Infrastructure made the largest contribution to revenue. Over the year Siemens pointed to strong demand for electrification, digitalisation and industrial AI, and to its position in fast-growing markets such as data centres.
Siemens: share price, chart and news

The Full Year Beats Guidance
| Fiscal year to September | 2026 | 2025 |
|---|---|---|
| Orders (comparable) | €108.2bn | €88.4bn |
| Revenue (comparable) | €83.4bn | €78.9bn |
| Profit Industrial Business | €13.3bn | €11.8bn |
| Industrial Business margin | 16.3% | 15.4% |
| Free cash flow | €12.1bn | €10.8bn |
| EPS pre-PPA | €11.76 | €12.95 |
| Dividend per share | €5.50 | €5.35 |
Comparable orders rose 25% and the order backlog grew to €143bn, from €117bn a year earlier. Revenue was up 8% on a comparable basis. EPS pre-PPA of €11.76 came in above the €11.20 to €11.50 range Siemens had set when it raised guidance after the third quarter.
Net income fell to €9.5bn from €10.4bn, but the earlier figure had included a €2.1bn gain on the sale of Innomotics. Digital business revenue rose 16% to €10.9bn. Software revenue in the Digital Industries unit grew 13% on a comparable basis to €7.2bn, and annual recurring revenue rose 12% to €6.1bn.
Chief executive Roland Busch called it an outstanding year and said "Industrial AI is an exceptional growth opportunity".
Higher Targets and the Healthineers Spin-Off
Siemens raised its mid-term ambition to comparable revenue growth of 7% to 11% a year, from 6% to 9%, and to double-digit annual growth in EPS pre-PPA, up from high single digits.
It also plans to transfer 34.1% of its stake in Siemens Healthineers to its own shareholders through a direct spin-off during fiscal 2027, at one Healthineers share for every two Siemens shares. Siemens will then deconsolidate Healthineers. It expects the medical technology business to be classified as a discontinued operation from the first quarter of fiscal 2027.
Two days before the results, on 10 November, Siemens agreed to buy Lauterbach, a maker of debugging and trace tools for embedded systems based in Hoehenkirchen, near Munich. Lauterbach has about 170 employees and had revenue of roughly €60m in 2025. No price was disclosed, and the deal is expected to close in the first half of 2027.
The 2027 Outlook
For fiscal 2027 Siemens expects comparable revenue growth of 9% to 11% and EPS pre-PPA of €10.20 to €10.80, both excluding Healthineers. On the same basis, fiscal 2026 EPS pre-PPA was €9.27, so the guidance implies growth of about 10% to 16.5%.
Fiscal 2027 targets by business
- Digital Industries: comparable revenue growth of 8% to 12%, profit margin of 20% to 22%
- Smart Infrastructure: comparable revenue growth of 11% to 13%, profit margin of 19.5% to 20.5%
- Mobility: comparable revenue growth of 6% to 8%, profit margin of 8% to 10%
- Group book-to-bill ratio above 1
The outlook excludes charges from legal and regulatory matters. With the backlog at €143bn, investors will judge whether the new growth range holds once Healthineers leaves the group, and how quickly the spin-off can be completed. The first verdict comes when Xetra trading opens.








